OABI

OmniAb (OABI)

OmniAb Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OABI

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/04	20 : 20	Business Wire	OmniAbが重鎖単一ドメイン抗体ニワトリプラットフォームに関する学術論文を米国免疫学会雑誌に発表	NASDAQ:OABI	OmniAb Inc
2024/06/04	05 : 05	Business Wire	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology	NASDAQ:OABI	OmniAb Inc
2024/05/20	21 : 05	Business Wire	OmniAb to Participate in the Jefferies Global Healthcare Conference	NASDAQ:OABI	OmniAb Inc
2024/05/16	05 : 05	Business Wire	OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit	NASDAQ:OABI	OmniAb Inc
2024/05/10	05 : 05	Business Wire	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2024/05/01	21 : 00	Business Wire	OmniAb to Participate in Five Investor Conferences in May	NASDAQ:OABI	OmniAb Inc
2024/04/22	21 : 00	Business Wire	OmniAb to Report First Quarter 2024 Financial Results on May 9	NASDAQ:OABI	OmniAb Inc
2024/03/21	05 : 05	Business Wire	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2024/02/26	22 : 00	Business Wire	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20	NASDAQ:OABI	OmniAb Inc
2024/02/20	22 : 00	Business Wire	OmniAb to Participate in Two Investor Conferences in March	NASDAQ:OABI	OmniAb Inc
2023/12/15	06 : 30	Business Wire	OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference	NASDAQ:OABI	OmniAb Inc
2023/11/10	07 : 55	Business Wire	OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event	NASDAQ:OABI	OmniAb Inc
2023/11/09	22 : 00	Business Wire	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2023/11/02	21 : 00	Business Wire	OmniAb to Participate in Two Investor Conferences in November	NASDAQ:OABI	OmniAb Inc
2023/11/01	22 : 00	Business Wire	OmniAb Appoints Steve Love to its Board of Directors	NASDAQ:OABI	OmniAb Inc
2023/11/01	05 : 28	Business Wire	OmniAb Announces Agenda for its Research & Technology Virtual Event	NASDAQ:OABI	OmniAb Inc
2023/10/12	21 : 00	Business Wire	OmniAb to Hold Research & Technology Virtual Event on November 9	NASDAQ:OABI	OmniAb Inc
2023/09/05	21 : 00	Business Wire	OmniAb to Participate in Two Investor Conferences in September	NASDAQ:OABI	OmniAb Inc
2023/08/11	05 : 05	Business Wire	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2023/08/08	05 : 05	Business Wire	OmniAb Announces the Passing of Director Sunil Patel	NASDAQ:OABI	OmniAb Inc
2023/07/31	21 : 00	Business Wire	OmniAb to Report Second Quarter 2023 Financial Results on August 10	NASDAQ:OABI	OmniAb Inc
2023/05/18	05 : 05	Business Wire	OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo	NASDAQ:OABI	OmniAb Inc
2023/05/11	20 : 00	Business Wire	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2023/05/01	21 : 00	Business Wire	OmniAb to Report First Quarter 2023 Financial Results on May 11	NASDAQ:OABI	OmniAb Inc
2023/04/25	21 : 00	Business Wire	OmniAb to Participate in Upcoming Investor Conferences in May	NASDAQ:OABI	OmniAb Inc
2023/03/31	05 : 05	Business Wire	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights	NASDAQ:OABI	OmniAb Inc
2023/03/09	22 : 00	Business Wire	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30	NASDAQ:OABI	OmniAb Inc
2023/02/07	22 : 00	Business Wire	OmniAb to Participate in Three Upcoming Investor Conferences	NASDAQ:OABI	OmniAb Inc
2022/12/01	22 : 47	GlobeNewswire Inc.	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable	NASDAQ:OABI	OmniAb Inc
2022/11/15	21 : 13	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OABI	OmniAb Inc